In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Texas Back Institute: Spine's Technology Laboratory

Executive Summary

From pedicle screws to spinal cages to artificial discs, the Texas Back Institute has been at the center of innovation of spine technology for nearly three decades. But it's not just technology that is changing: so are the nature and tenor of relationships between surgeons and product companies, and here too, TBI finds itself right in the middle.

You may also be interested in...



Dynamic Stabilization Rocks Spine

In the US acceptance of dynamic stabilization devices (DYNs) has been strong owing to the compelling advantages of DYNs over artificial discs, including that they can be implanted from a posterior route, do not violate the disc space and the procedure is reversible. Rather being an alternative to fusion, artificial discs will likely compete with DYNs.

IST: The Big Bang Theory of Device Innovation

Assembling a Dream Team of surgeons, including those of The Texas Back Institute, as well as leading medical device companies, IST sought to create an incubator in spine unparalleled in its ability to bring new technology to market. The only thing is, the model didn't work. Now, IST has shifted gears and is pursuing a mega-roll up strategy.

Cullinan Changes Tracks, Moving Lymphoma Bispecific Into Autoimmune

The company will discontinue its trial of the CD19-directed bispecific CLN-978 in NHL and develop it in inflammatory diseases, where it could have an edge over CAR-Ts.

Topics

Related Companies

Related Deals

Latest Headlines
See All
UsernamePublicRestriction

Register

IV002574

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel